1. Spain Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Biotechnology Assets SA

Biotechnology Assets SA

BBME:BST
0.18
EUR
-0.01
(-4.70%)
14.25MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.21
0.42
0.23
0.26
2.42
0.59
0.05
0.06
0.07
0.05
0.06
0.04
0.04
- -
Basic EPS, GAAP
0.11
0.27
-0.04
-0.22
-2.4
-0.43
-0.26
-0.22
-0.07
-0.04
0.03
-0.04
-0.03
- -
Free Cash Flow per Basic Share
- -
-0.21
-0.2
-0.11
-3
-0.62
-0.58
0.21
-0.05
-0.04
- -
-0.01
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1.02
1.73
1.65
1.59
2.9
0.45
0.2
0.1
0.1
0.07
0.12
0.1
0.1
0.1
Tangible Book Value per Share
0.51
0.63
0.45
0.11
2.64
0.08
-0.16
-0.16
-0.1
-0.09
-0.01
0.01
0.04
0.04
Basic Weighted Avg Shares
4
4
5
5
5
39
39
39
46
54
58
66
73
70
Sales/Revenue/Turnover
1
2
1
1
12
23
2
3
3
3
4
3
3
- -
Operating Margin (%)
25.12
17.63
-56.23
-61.51
-91.28
-58.99
-105.61
-46.63
-49.81
-65.26
82.7
-88.14
-22.85
- -
Depreciation Expense
1
1
1
1
1
3
4
2
2
2
2
2
2
- -
Net Income, GAAP
- -
1
- -
-1
-12
-17
-10
-9
-3
-2
2
-3
-2
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
32.23
- -
- -
- -
Profit Margin (%)
54.35
63.46
-18.34
-86.55
-99.45
-72.81
-473.43
-340.91
-97.65
-74.35
43.7
-116.02
-61.99
- -
Working Capital
- -
2
2
- -
5
-3
1
-6
1
- -
- -
-1
1
1
LT Debt
- -
5
1
1
22
13
11
2
3
10
5
2
2
2
Total Equity
4
8
8
8
15
18
8
4
4
4
7
7
7
7
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
13.84
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
12.2
- -
- -
- -
Return on Common Equity (%)
13.33
20.03
-2.53
-14.54
-107.14
-104.4
-78.83
-147.09
-71.03
-45.64
29.39
-43.89
-28.23
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
3
2
2
LT Borrowings
2
3
2
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
66
68
73
Market Capitalization
18
29
14

Working Capital

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
4
3
5
Cash, Cash Equivalents & STI
- -
1
1
Accounts Receivable, Net
3
2
4
Inventories
- -
- -
- -
Total Current Liabilities
5
3
3
Payables & Accruals
- -
- -
- -
ST Debt
3
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.05%
15.46%
5.33%
Free Cash Flow
242.87%
-16.74%
-55.19%
Net Income, GAAP
84.36%
-120.23%
-34.32%
Sales/Revenue/Turnover
91.26%
7.49%
22.91%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
4
2024
- -
- -
3
2025
- -
- -
3

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.03
2024
- -
- -
-0.04
2025
- -
- -
-0.03

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Manuel Lopez Nieto
Full Time Employees
26
Sector
Health technology
Industry
Biotechnology
Address
Av. del Desarrollo Tecnológico, 11 Jerez de la Frontera AN Spain 11591
IPO Date
Jun 14, 2011
Website
adlbionatur.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Biotechnology Assets S.A. (BST.MC) develops and markets biotechnological assets for applications in the biopharmaceutical, agrochemical, cosmetic, veterinary, and chemical industry sectors. The company offers SPLITTERA technology, an innovative, universal, and robust solution for site-specific conjugation of proteins; proprietary split-inteins under the ZIP Solutions brand including Click-gene for gene therapy, Click-bio for immunotherapy, Click-Dx for in vitro diagnostics, Click-VLP for smart vaccines, Vacc-Zera for RNA and DNA vaccines, and Click-DSP for affinity-based protein purification; as well as unique biotech assets for human and animal health under the Biat brand. Through its subsidiaries, it promotes Biobide's zebrafish animal model services for tailor-made toxicity and efficacy testing, combining in vitro and in vivo features, alongside ZIP Solutions and Biat assets via a global commercial network. The company operates in Spain and internationally, targeting health, beauty, wellness, and related industries as a biotech fermentation-focused contract manufacturing organization (CMO/CDMO). Founded in 1954 and headquartered in Cádiz, Spain, with key facilities in Jerez de la Frontera, it employs approximately 34 people and generated trailing twelve-month revenue of EUR 2.51 million as of the latest reporting. Formerly known as ADL Bionatur Solutions S.A., the company rebranded to Biotechnology Assets S.A. and maintains its core focus on research, development, production, and commercialization of biotechnological solutions for health and welfare improvements in people and animals.